Clinical - ABL SA : ABL SA

Read more

EMRs - Registries - Integration tool

Read more

Read more

Read more

Clinical solutions

Discover our solutions

Clinical applications

Discover our applications

UltraGene Combo2Screen SARS-CoV-2 Assay Now Registered at the INVIMA in Colombia

Jan 11, 2021

We are pleased to announce today that the RT-PCR test for COVID-19 detection UltraGene® Combo2Screen SARS-CoV-2 assay is now officially registered at the INVIMA in Colombia. To learn more about UltraGene® Combo2Screen SARS-CoV-2 assay, please visit https://www.ablsa.com/laboratory-applications/ultra…
Read more
UltraGene Combo2Screen SARS-CoV-2 Assay Now Registered at the ALMBiH in Bosnia

Jan 11, 2021

We are pleased to announce today that the RT-PCR test for COVID-19 detection UltraGene® Combo2Screen SARS-CoV-2 assay is now officially registered at the ALMBiH in Bosnia. To learn more about UltraGene® Combo2Screen SARS-CoV-2 assay, please visit https://www.ablsa.com/laboratory-applications/ultrage…
Read more
Highly Satisfactory Accuracy for the UltraGene Combo2Screen SARS-CoV-2 Assay on the QCMD 2020 SARS-CoV-2 EQA Programme

Dec 18, 2020

We are pleased to announce that the UltraGene Combo2Screen SARS-CoV-2 Assay has obtained Highly Satisfactory results (with a 100% accuracy for qualitative detection of all QCMD blinded samples, including with lowest viral load) in the context of the QCMD 2020 SARS-CoV-2 EQA Programme (SCV2_20…
Read more

New Publication on DeepChek®-HCV Drug Resistance Assays and Software (Virology Journal)

Jul 17, 2020

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols Caputo et al. Virology Journal (2020) 17:103 https://doi.org/10.1186/s12985-020-01381-3 Abstract Background: Notwithstanding the efforts of direct-acting antivirals (DAAs) for…
Read more
ABL Appointed as the Exclusive Distributor of all NimaGen sequencing products for France, Belgium and Luxembourg

Jul 15, 2020

We are pleased to announce that Nimagen appointed ABL as its exclusive distribution partner for Sequencing Products in France, Belgium and Luxembourg. The partnership was formalized on March 17th 2020 and will help all labs involved in sequencing to get access to robust and cost-effective solutions…
Read more
Advanced Biological Laboratories (ABL) Releases the First & Unique Commercial CE-IVD Registered COVID-19 rRT-PCR Assay Validated also for Human Saliva Specimens

Jul 06, 2020

Single well rRT-PCR assay, including highly sensitive detection of 2 targets and housekeeping internal control, with full automation Luxembourg (Luxembourg), Metz (France), — July 06 — Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its UltraGene® Combo2Screen SARS-CoV…
Read more

SARS-CoV-2 PCR Assay Now Approved for Human Saliva Specimens

Jun 17, 2020

First rt-PCR detection kit CE marked for nasopharyngeal and saliva samples. Improve COVID-19 management with non-invasive, open and sensitive assay. Luxembourg (Luxembourg), Metz (France), — June 17 — Advanced Biological Laboratories (ABL) announced today the validation of its CE-IVD UltraGene® Com…
Read more
Highly Satisfactory Accuracy for the UltraGene Combo2Screen SARS-CoV-2 Assay on the QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study

May 29, 2020

We are pleased to announce that the UltraGene Combo2Screen SARS-CoV-2 Assay has obtained Highly Satisfactory results (with a 100% accuracy for qualitative detection of all QCMD blinded samples, including with lowest viral load) in the context of the QCMD 2020 Coronavirus Outbreak Preparedness EQA Pi…
Read more
Advanced Biological Laboratories Receives CE-IVD Registration for its UltraGene Combo2Screen SARS-CoV-2 Assay

May 21, 2020

Optimizing COVID-19 management through highly sensitive SARS-CoV-2 detection test. Luxembourg (Luxembourg), Metz (France) — May 21— Advanced Biological Laboratories (ABL) announced today the CE-IVD registration of its UltraGene® Combo2Screen SARS-CoV-2 assay, now available for in-vitro diagnostics u…
Read more